Teclistamab (Tecvayli) is an off-the-shelf first-in-class bispecific monoclonal antibody shown in the MajesTEC-1 trial to ...
Hematologists and oncologists from UC San Francisco shared research results and clinical guidance at the world’s premier meeting for malignant and non-malignant hematology at the American Society of ...
6don MSN
US to pay $450K to wildfire crews who developed cancer - and cover the cost of the kids’ college
Multiple studies have found that firefighters face an elevated risk of certain cancers due to occupational exposures.
Based in New Brunswick, New Jersey, Johnson & Johnson (JNJ) is a diversified global healthcare leader. The company develops ...
Experts discuss the evolving role of bispecific antibodies in multiple myeloma, highlighting treatment advancements and ...
At ASH 2025, iMMagine-1 data showed that anito-cel has a favorable and durable safety profile with low rates of severe CRS, neurotoxicity, and infections.
Patients share their emotional journeys and coping strategies after cancer diagnoses, highlighting the importance of support ...
PERSEUS trial findings suggest that modern myeloma therapies could lead to survival rates similar to age-matched controls. KLN-1010, an off-the-shelf gene therapy, demonstrated promising MRD-negative ...
Regeneron is set for a turnaround as Dupixent and Libtayo drive growth, and 2026 pipeline catalysts may boost revenue. See why REGN stock is a strong buy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback